Literature DB >> 14745153

Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats.

Eikan Koh1, Tsuneyuki Nakamura, Hiroaki Takahashi.   

Abstract

BACKGROUND: Clinical methods for the early detection of doxorubicine (adriamycin; ADR) -induced cardiotoxicity have not been established. This study prospectively investigated whether atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and cardiac troponin T (TnT) are predictors for ADR-induced cardiotoxicity, and examined the correlations between the serum concentrations of these biomarkers and the functional alternations associated with ADR-induced myocardial damage. METHODS AND
RESULTS: Male Wistar rats were injected weekly with 2 mg/kg of ADR via the tail vein for 8 weeks to induce cardiotoxicity. Echocardiograms of each ether anesthetized rat were taken at 6, 8, 10 and 12 weeks after the first administration of ADR, and blood samples collected from the tail vein were used to quantify plasma ANP and BNP, and serum TnT after echocardiography. Plasma BNP and serum TnT significantly increased from 6 to 12 weeks (81.5 to 173.3 pg/ml (p<0.001), <0.01 to 1.09 ng/ml (p<0.05), respectively) with deterioration of left ventricular % fractional shortening (%FS) (58.6% to 36.8%). The %FS significantly correlated with TnT (r=-0.51, p<0.001) and BNP (r=-0.75, p<0.0001); however, the increase of TnT was antecedent to the increase of BNP and the deterioration of %FS.
CONCLUSION: Plasma BNP and serum TnT concentrations, especially TnT, measured by this highly sensitive method are useful predictors for ADR-induced cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745153     DOI: 10.1253/circj.68.163

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  18 in total

1.  Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.

Authors:  Tanaya R Vaidya; Hardik Mody; Yesenia L Franco; Ashley Brown; Sihem Ait-Oudhia
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 4.009

2.  Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies.

Authors:  Ryoji Taniguchi; Yukihito Sato; Yukiko Nishio; Takeshi Kimura; Toru Kita
Journal:  Heart Vessels       Date:  2006-11-27       Impact factor: 2.037

3.  Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function.

Authors:  Reid Hayward; David Hydock; Noah Gibson; Stephanie Greufe; Eric Bredahl; Traci Parry
Journal:  J Physiol Biochem       Date:  2012-08-14       Impact factor: 4.158

Review 4.  Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.

Authors:  Dhssraj Singh; Akanksha Thakur; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2015-06

5.  Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway.

Authors:  Ferhat Dindaş; Hüseyin Güngör; Mehmet Ekici; Pınar Akokay; Füsun Erhan; Mustafa Doğduş; Mehmet Birhan Yılmaz
Journal:  Anatol J Cardiol       Date:  2021-11       Impact factor: 1.596

6.  Cardioprotective roles of sestrin 1 and sestrin 2 against doxorubicin cardiotoxicity.

Authors:  Ruiting Li; Yin Huang; Ian Semple; Myungjin Kim; Zunjian Zhang; Jun Hee Lee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-04-26       Impact factor: 4.733

7.  A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity.

Authors:  Andrei Maksimenko; Franco Dosio; Julie Mougin; Annalisa Ferrero; Severine Wack; L Harivardhan Reddy; Andrée-Anne Weyn; Elise Lepeltier; Claudie Bourgaux; Barbara Stella; Luigi Cattel; Patrick Couvreur
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-02       Impact factor: 11.205

8.  Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer.

Authors:  Jia Lin; Yan Yu; Sarah Shigdar; Ding Zhi Fang; Jun Rong Du; Ming Q Wei; Andrew Danks; Ke Liu; Wei Duan
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

9.  Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines.

Authors:  Beata Mladosievicova; Dagmar Urbanova; Eva Radvanska; Peter Slavkovsky; Iveta Simkova
Journal:  J Exp Clin Cancer Res       Date:  2012-10-11

10.  The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and Doxorubicin.

Authors:  Agnieszka Korga; Jaroslaw Dudka; Franciszek Burdan; Justyna Sliwinska; Slawomir Mandziuk; Katarzyna Dawidek-Pietryka
Journal:  Oxid Med Cell Longev       Date:  2012-02-26       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.